Literature DB >> 9024954

Dehydroepiandrosterone (DHEA) treatment of depression.

O M Wolkowitz1, V I Reus, E Roberts, F Manfredi, T Chan, W J Raum, S Ormiston, R Johnson, J Canick, L Brizendine, H Weingartner.   

Abstract

Dehydroepiandrosterone (DHEA) and its sulfate, DHEA-S, are plentiful adrenal steroid hormones that decrease with aging and may have significant neuropsychiatric effects. In this study, six middle-aged and elderly patients with major depression and low basal plasma DHEA f1p4or DHEA-S levels were openly administered DHEA (30-90 mg/d x 4 weeks) in doses sufficient to achieve circulating plasma levels observed in younger healthy individuals. Depression ratings, as well as aspects of memory performance significantly improved. One treatment-resistant patient received extended treatment with DHEA for 6 months: her depression ratings improved 48-72% and her semantic memory performance improved 63%. These measures returned to baseline after treatment ended. In both studies, improvements in depression ratings and memory performance were directly related to increases in plasma levels of DHEA and DHEA-S and to increases in their ratios with plasma cortisol levels. These preliminary data suggest DHEA may have antidepressant and promemory effects and should encourage double-blind trials in depressed patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9024954     DOI: 10.1016/s0006-3223(96)00043-1

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  40 in total

Review 1.  [New developments in pharmacotherapy of depression].

Authors:  R Rupprecht; Th C Baghai; H-J Möller
Journal:  Nervenarzt       Date:  2003-05-10       Impact factor: 1.214

Review 2.  Neurosteroids: endogenous role in the human brain and therapeutic potentials.

Authors:  Doodipala Samba Reddy
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

Review 3.  Endocrine disturbances in depression.

Authors:  M A Tichomirowa; M E Keck; H J Schneider; M Paez-Pereda; U Renner; F Holsboer; G K Stalla
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

Review 4.  Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders.

Authors:  Teruo Hayashi; Shang-Yi Tsai; Tomohisa Mori; Michiko Fujimoto; Tsung-Ping Su
Journal:  Expert Opin Ther Targets       Date:  2011-03-05       Impact factor: 6.902

5.  Ionized prodrugs of dehydroepiandrosterone for transdermal iontophoretic delivery.

Authors:  S Laneri; A Sacchi; E A di Frassello; E Luraschi; P Colombo; P Santi
Journal:  Pharm Res       Date:  1999-12       Impact factor: 4.200

Review 6.  Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders.

Authors:  Teruo Hayashi; Tsung-Ping Su
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 7.  Effect of reproductive hormones and selective estrogen receptor modulators on mood during menopause.

Authors:  Claudio N Soares; Jennifer R Poitras; Jennifer Prouty
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 8.  Therapeutic options for treatment-resistant depression.

Authors:  Richard C Shelton; Olawale Osuntokun; Alexandra N Heinloth; Sara A Corya
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

9.  Glucocorticoid receptor dysfunction: consequences for the pathophysiology and treatment of mood disorders.

Authors:  Aju Abraham; Stuart Watson; Allan H Young
Journal:  Indian J Psychiatry       Date:  2003-04       Impact factor: 1.759

10.  The effects of galantamine hydrobromide treatment on dehydroepiandrosterone sulfate and cortisol levels in patients with chronic fatigue syndrome.

Authors:  Tayfun Turan; Hasan Basri Izgi; Saliha Ozsoy; Fatih Tanrıverdi; Mustafa Basturk; Akif Asdemir; Aslı Beşirli; Ertugrul Esel; Seher Sofuoglu
Journal:  Psychiatry Investig       Date:  2009-06-23       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.